Immunovant, Inc. (IMVT) 은(는) 상장 기업입니다 헬스케어 섹터의 바이오 산업에서 운영. 본사 소재지는 New York City, NY, 미국. 현재 CEO는 Eric Venker.
IMVT 을(를) 보유 IPO 날짜 2019-06-21, 362 명의 정규직 직원, 에 상장 NASDAQ Global Select, 시가총액 $5.4B.
Immunovant, Inc. is a clinical-stage biopharmaceutical company developing monoclonal antibodies to treat autoimmune diseases. The company's lead candidate, batoclimab, is a fully human monoclonal antibody that selectively inhibits the neonatal fragment crystallizable receptor and is currently in Phase IIa clinical trials for myasthenia gravis and thyroid eye disease, with Phase II trials recently initiated for warm autoimmune hemolytic anemia. Founded in 2018 and headquartered in New York, Immunovant operates as a subsidiary of Roivant Sciences Ltd.
